Browsing: Taxonomy > Drug development
NICE have approved Alecensa for use on the NHS, following positive data from a Phase II trial, including a reduced risk of brain metastasis.
Clinical data demonstrates improvement in metastatic gastric cancer patient overall survival in comparison with the placebo.
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
A novel three-dimensional high-throughput screening approach allows researchers to identify inducers of a mutant KRAS selective lethal phenotype.
To mark World Health Day we spoke with Ivo Abraham from the University of Arizona (AZ, USA) about the role that biosimilars play in expanding access to cancer treatments, particularly in regards to the biosimilar filgrastim-sndz.
This World Health Day the WHO is calling for robust steps towards universal healthcare with actions on a policy and an individual level. Find out about some of the issues in global health from across our sister sites.
In this interview find out what advancements have been made in the field of biosimilars and how they are helping improve access to cancer medicines.
Larotrectinib becomes the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.
Phase III IM power150 study has demonstrated that atezolizumab and bevacizumab plus carboplatin and paclitaxel helped individuals with advanced lung cancer live longer compared to avastin plus carboplatin and paclitaxel.